Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Randomized, Double-blind, Placebo-controlled, Dose-ranging, Multicenter Study to Evaluate the Efficacy and Safety of Isuzinaxib in Subjects With Diabetic Kidney Disease

NCT06962098 is registered in ClinicalTrials.gov with Aptabio Therapeutics, Inc. as lead sponsor.

NCT NCT06962098
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06962098 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Randomized, Double-blind, Placebo-controlled, Dose-ranging, Multicenter Study to Evaluate the Efficacy and Safety of Isuzinaxib in Subjects With Diabetic Kidney Disease
Lead sponsor
Aptabio Therapeutics, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
May 26, 2025
Completion date
June 30, 2028
Enrollment
186 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic kidney disease (dkd)